StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3057% above fair value
$251.41+0.62 (+0.25%)

Close on Nov 18, 2026Market cap $37.16BP/E 107.4Yield –

Biogen revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Biogen's revenue for the twelve months ending Sep 30, 2026 was $10.30B, up 2.3% year over year. For fiscal 2025 it was $9.89B, up 2.2% from the year before. Over ten years it grew -0.8% a year on average. The highest annual figure on record is $14.38B in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.89B+2.2%
FY2024Dec 31, 2024$9.68B-1.6%
FY2023Dec 31, 2023$9.84B-3.3%
FY2022Dec 31, 2022$10.17B-7.4%
FY2021Dec 31, 2021$10.98B-18.3%
FY2020Dec 31, 2020$13.44B-6.5%
FY2019Dec 31, 2019$14.38B+6.9%
FY2018Dec 31, 2018$13.45B+9.6%
FY2017Dec 31, 2017$12.27B+7.2%
FY2016Dec 31, 2016$11.45B+6.4%
FY2015Dec 31, 2015$10.76B+10.9%
FY2014Dec 31, 2014$9.70B+40.0%
FY2013Dec 31, 2013$6.93B+25.7%
FY2012Dec 31, 2012$5.52B+9.3%
FY2011Dec 31, 2011$5.05B+7.0%
FY2010Dec 31, 2010$4.72B+7.7%
FY2009Dec 31, 2009$4.38B+6.8%
FY2008Dec 31, 2008$4.10B+29.2%
FY2007Dec 31, 2007$3.17B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.80B+10.6%
Q2 FY2026Jun 30, 2026$2.74B+3.4%
Q1 FY2026Mar 31, 2026$2.48B+1.9%
Q4 FY2025Dec 31, 2025$2.28B-7.1%
Q3 FY2025Sep 30, 2025$2.53B+2.8%
Q2 FY2025Jun 30, 2025$2.65B+7.3%
Q1 FY2025Mar 31, 2025$2.43B+6.1%
Q4 FY2024Dec 31, 2024$2.45B+2.9%
Q3 FY2024Sep 30, 2024$2.47B-2.5%
Q2 FY2024Jun 30, 2024$2.46B+0.4%
Q1 FY2024Mar 31, 2024$2.29B-7.0%
Q4 FY2023Dec 31, 2023$2.39B-6.2%
Q3 FY2023Sep 30, 2023$2.53B+0.9%
Q2 FY2023Jun 30, 2023$2.46B-5.1%
Q1 FY2023Mar 31, 2023$2.46B-2.7%
Q4 FY2022Dec 31, 2022$2.54B-6.9%
Q3 FY2022Sep 30, 2022$2.51B-9.7%
Q2 FY2022Jun 30, 2022$2.59B-6.7%
Q1 FY2022Mar 31, 2022$2.53B-6.0%
Q4 FY2021Dec 31, 2021$2.73B-4.2%
Q3 FY2021Sep 30, 2021$2.78B-17.7%
Q2 FY2021Jun 30, 2021$2.78B-24.6%
Q1 FY2021Mar 31, 2021$2.69B-23.8%
Q4 FY2020Dec 31, 2020$2.85B-22.3%
Q3 FY2020Sep 30, 2020$3.38B-6.2%
Q2 FY2020Jun 30, 2020$3.68B+1.8%
Q1 FY2020Mar 31, 2020$3.53B+1.3%
Q4 FY2019Dec 31, 2019$3.67B+4.1%
Q3 FY2019Sep 30, 2019$3.60B+4.7%
Q2 FY2019Jun 30, 2019$3.62B+7.8%
Q1 FY2019Mar 31, 2019$3.49B+11.5%
Q4 FY2018Dec 31, 2018$3.53B+6.6%
Q3 FY2018Sep 30, 2018$3.44B+11.7%
Q2 FY2018Jun 30, 2018$3.36B+9.0%
Q1 FY2018Mar 31, 2018$3.13B+11.4%
Q4 FY2017Dec 31, 2017$3.31B+15.1%
Q3 FY2017Sep 30, 2017$3.08B–
Q2 FY2017Jun 30, 2017$3.08B–
Q1 FY2017Mar 31, 2017$2.81B–
Q4 FY2016Dec 31, 2016$2.87B–

More Biogen figures

See a number that looks wrong?